openPR Logo
Press release

greenovation increases investment in GMP-compliant process development for production of therapeutic proteins

08-28-2008 03:36 PM CET | Health & Medicine

Press release from: greenovation Biotech GmbH

Mosses

Mosses

The primary objective of the investment is the implementation of a stable production platform for the manufacture of glycoproteins for industrial pharmaceutical applications, in accordance with GMP (Good Manufacturing Practice) guidelines - Gregor Mirow succeeds Hans Bodo Hartmann as the new managing director of greenovation Biotech GmbH

Heilbronn, Germany – August 28th, 2008 – greenovation Biotech GmbH is investing in an accelerated implementation of its technical production platform in order to satisfy increasing future demand in the pharmaceutical industry for therapeutic proteins created by the greenovation® System.

Research in terms of protein production in moss, and the associated possibility of enhancing the gycosylation of proteins are the core of greenovation’s business, resulting in the manufacture of protein prototypes for pharmaceutical research. The company will significantly increase its investment in the development of industrial processes for the production of pharmaceutical proteins, compliant with pharmaceutical standards.

Gregor Mirow has joined greenovation as CEO and managing director, succeeding Hans Bodo Hartmann, who since 2005 has successfully taken greenovation’s R&D efforts to market, turning the company into a successful market player with a top class client portfolio within the international pharmaceutical and biotech industry. Hans Bodo Hartmann comments: “greenovation is a well known company in the pharmaceutical industry and, by virtue of its bryotechnology, has an outstanding position from which to advance into the upcoming phase of industrial production.”

Gregor Mirow has held several senior executive positions in the international biotechnology and pharmaceutical industry, and has considerable experience in the field of biotechnological production.

“Protein production in moss offers the pharmaceutical industry an opportunity to produce enhanced proteins in a new production system at competitive prices. greenovation Biotech GmbH invests into its ability to provide GMP-compliant cell-line development and production processes to supply superior proteins to the pharmaceutical industry more rapidly and more cost-effectively. I am really looking forward to working with this successful and innovative team”, said Gregor Mirow.

greenovation is working with bryotechnology in photo bioreactors to create human proteins, such as antibodies for medical diagnosis and treatment. A 100 L photo bioreactor was recently installed at the Freiburg laboratories of greenovation.

With Bryo-Speed™ and Bryo-Master™, greenovation Biotech GmbH has developed two fast production systems for research scale product evaluation and protein property assessment of its glyco-enhanced products. Bryo-Speed™ provides a vehicle to supply small quantities of glycoproteins to assess system feasibility and/or product evaluation within four to six weeks.
Bryo-Master™ is based on stable production cell lines allowing the production of larger quantities for further research and evaluation of the material for early pre-clinical studies within months.

Contact greenovation:
Andreas Kranzusch
Chief Financial Officer
T: +49-761-470990
E: info@greenovation.com

Public & Media Relations:
Jörn Gleisner
fr financial relations gmbh
T:+49-69-959083-20
E: j.gleisner@financial-relations.de

greenovation Biotech GmbH
greenovation Biotech GmbH is a developer of Glyco-Engineering and protein production technologies in moss, and a service-provider and supplier to the pharmaceutical and biotech industries. Greenovation offers contract research, cell-line and production process development and contract manufacturing. The privately held biotechnology company, headquartered in Heilbronn, Germany, with research facilities in Freiburg, was incorporated in September 1999 as a spin-off of the University of Freiburg. Venture capital investors are L-EigenkapitalAgentur, Karlsruhe, Mediport Venture, Berlin, the SeedGruppe, Tuebingen and Zukunftsfonds, Heilbronn.

Bryotechnology
Greenovation's core competency lies in the efficacy-enhancement and production of pharmaceutically potent glycoproteins in contained photobioreactors. The production platform - Bryotechnology, - is based on protein production in bryophytes (mosses). Recombinant antibodies and other glycoproteins can be efficiently produced in the moss bioreactors, with high flexibility and control over the carbohydrate structure. Such Glyco-Engineering can, for example, be exploited to produce antibodies with high potency in targeted cell-killing by ADCC - a clinically validated mechanism for the targeted removal of cancer cells.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release greenovation increases investment in GMP-compliant process development for production of therapeutic proteins here

News-ID: 52185 • Views: 1177

More Releases from greenovation Biotech GmbH

greenovation launches Bryo-Speed™ and Bryo-Master™ for the production of the …
From pilot study to stable production: in Bryo-Speed™ and Bryo-Master™ greenovation presents a production platform for custom-made pharmaceuticals – Presentation of the new products at BioProduction 2007 in Berlin Heilbronn/ Germany – November 1st 2007 – greenovation.com. Bryo-Speed™ and Bryo-Master™ are greenovation’s innovative production systems for the effective optimization and creation of pharmaceutically highly efficient glycoproteins: The production platform is based on bryotechnology which has been developed by greenovation
Joint process development between Sartorius Stedim Biotech and greenovation Biot …
greenovation.com - Major step taken towards process-scale implementation of proprietary bryotechnology developed by greenovation - In demand - Sartorius expertise in fermentation and purification process engineering Heilbronn/ Göttingen – Oktober 12, 2007. Sartorius Stedim Biotech GmbH, headquartered in Goettingen, and greenovation Biotech GmbH in Heilbronn, Germany, agreed to collaborate on the project of process-scale implementation of the innovative, plant-based bryotechnology developed by greenovation. In the past years, greenovation Biotech and Sartorius Stedim
greenovation Biotech GmbH gets first US Patent Granted on Glyco-Engineering Port …
greenovation Biotech GmbH announces the granting of their first US patent in the area of plant-based glyco-engineering. This patent offers wide-ranging protection for the targeted processing of a plant-specific sugar residue. First Patent from a Complete Patent Family Heilbronn – June 20, 2007. Scientists at greenovation Biotech GmbH have been able to build on many years of experience in the area of the design of production strains in moss, in their work

All 4 Releases


More Releases for Mosses

OpenBooking in the Alpes vaudoises
On 20 June the website of the touristic region Alpes vaudoises launched their new booking search with the OpenBooking white label. The center stage of the website takes OpenBooking. By the integration of multiple booking provider like Tomas, Interhome, Reka and Citi the amount of online bookable accommodations raised significantly from 250 to now 461. Further connections to additional booking providers and quality labels are already planned. The booking search
Biologic Therapeutics Market - Demand for low-cost Technology 2025
Global Biologic Therapeutics Market: Snapshot The branch of science that deals with manufacturing medicines and pharmaceutical products based on biological origins is called biological therapeutics. Any pharmaceutical drug product manufactured from semi-synthesized and biological sources is included under this field. Owing to rapid advances experienced by this sector, a distinct biologic therapeutics market has formed. This market is mainly being driven by a rising demand for better healthcare treatments occurring all
Global Seeds Market: Market Estimation, Dynamics, Regional Share, Trends, Compet …
Global Seeds Market: Seed is an embryonic plant which is enclosed in the protective covering. Seed formation is the reproduction process in seed plants, the spermatophytes including angiosperm and gymnosperm plants. Seeds are the products of reproduction of ripened ovule, after the fertilization by pollen and some growth within mother plant. The embryo is developed from zygote and seed coat from ovule’s integuments. Seed is an important development in reproduction
Latin America Turf and Ornamental Grass Protection Is Anticipated To Reach USD U …
Latest niche market research study on “Turf and Ornamental Grass Protection Market by Type, by Material, and by Application Latin America Opportunity Analysis and Industry Forecast 2021" published at Orbisresearch.com The Latin American Turf and Ornamental Grass Protection market has been estimated at USD 0.57 Billion in 2016 and is projected to reach USD 0.76 Billion by 2021, at a CAGR of 5.80% during the forecast period from 2016 to 2021.
High Pressure Cleaning Sydney Offers Excellent Cleaning Services In Sydney
Located in Glenwood, New South Wales, High Pressure Cleaning Sydney was established with an aim to offer the best cleaning services including pressure washing to their client’s at the most affordable prices. Catering to both metropolitan and suburbs, they offer their services to home owners, property managers, business owners and factory owners. Apart from this, they extend their services to schools, colleges, petrol stations, restaurants, convenience stores, parking lots, shopping
greenovation launches Bryo-Speed™ and Bryo-Master™ for the production of the …
From pilot study to stable production: in Bryo-Speed™ and Bryo-Master™ greenovation presents a production platform for custom-made pharmaceuticals – Presentation of the new products at BioProduction 2007 in Berlin Heilbronn/ Germany – November 1st 2007 – greenovation.com. Bryo-Speed™ and Bryo-Master™ are greenovation’s innovative production systems for the effective optimization and creation of pharmaceutically highly efficient glycoproteins: The production platform is based on bryotechnology which has been developed by greenovation